Kezar Life Sciences, Inc.
KZR
$4.60
$0.1974.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 16.03M | 16.24M | 16.30M | 17.17M | 22.64M |
| Gross Profit | -16.03M | -16.24M | -16.30M | -17.17M | -22.64M |
| SG&A Expenses | 5.55M | 5.71M | 5.60M | 6.54M | 5.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.58M | 21.95M | 21.90M | 23.71M | 28.40M |
| Operating Income | -21.58M | -21.95M | -21.90M | -23.71M | -28.40M |
| Income Before Tax | -20.22M | -20.31M | -21.55M | -21.66M | -32.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.22M | -20.31M | -21.55M | -21.66M | -32.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.22M | -20.31M | -21.55M | -21.66M | -32.26M |
| EBIT | -21.58M | -21.95M | -21.90M | -23.71M | -28.40M |
| EBITDA | -21.32M | -21.69M | -21.64M | -23.45M | -28.12M |
| EPS Basic | -5.54 | -2.78 | -2.96 | -2.98 | -4.44 |
| Normalized Basic EPS | -3.46 | -1.74 | -1.72 | -1.86 | -2.24 |
| EPS Diluted | -5.54 | -2.78 | -2.96 | -2.98 | -4.44 |
| Normalized Diluted EPS | -3.46 | -1.74 | -1.72 | -1.86 | -2.24 |
| Average Basic Shares Outstanding | 7.30M | 7.30M | 7.28M | 7.28M | 7.27M |
| Average Diluted Shares Outstanding | 7.30M | 7.30M | 7.28M | 7.28M | 7.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |